From this study, they concluded that “HA-oligosaccharides suppressed progression of bone metastasis in breast cancer via interruption of endogenous HA-CD44 interaction and, as such, could be a novel therapeutic candidate to limit bone metastasis of breast cancer.” Moreover, small HA oligomers have shown their potential during in vivo treatments by suppressing tumor growth and/or inducing tumor regression in experiments using xenografts of several tumor types [17, 86, 96, 98, 101, 102]. The gene discussed is CD44; the disease is breast carcinoma.